What is a more affordable alternative to efinaconazole (Jublia) for a patient with onychomycosis (toe fungus) who was suggested ciclopirox by the pharmacy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Switching from Efinaconazole to Ciclopirox for Onychomycosis

Ciclopirox 8% nail lacquer is a reasonable and more affordable alternative to efinaconazole, though you should understand it has lower efficacy—expect mycological cure rates of only 34% compared to efinaconazole's 50%, with clinical cure rates as low as 8%. 1, 2

Key Efficacy Differences You Need to Know

The pharmacy's suggestion of ciclopirox is appropriate from a cost perspective, but the trade-off in effectiveness is substantial:

  • Efinaconazole achieves mycological cure rates approaching 50% and complete cure in 15% of patients after 48 weeks 1
  • Ciclopirox achieves only 34% mycological cure versus 10% with placebo, with clinical cure of just 8% versus 1% with placebo 1, 2
  • Direct comparison studies show efinaconazole is more effective in vitro than ciclopirox against dermatophytes, yeasts, and non-dermatophyte molds 3

When Ciclopirox Is Most Appropriate

Ciclopirox works best for limited disease—specifically superficial white onychomycosis or early distal lateral subungual onychomycosis when less than 80% of the nail plate is affected without lunula involvement. 1, 4

If your patient has more extensive disease, ciclopirox monotherapy will likely fail, and you should consider:

  • Oral terbinafine 250 mg daily for 12-16 weeks (first-line systemic therapy) 1
  • Combination therapy: ciclopirox plus oral terbinafine achieves 66.7% mycological cure in moderate-to-severe cases 4

Dosing Protocol for Ciclopirox

  • Apply 8% nail lacquer once daily to affected toenails 1, 2
  • Treatment duration: up to 48 weeks for toenails (24 weeks for fingernails) 1, 2
  • Remove as much diseased nail as possible by gentle filing before each application 1

Critical Pitfall to Avoid

Clinical improvement does not equal mycological cure—cure rates are often 30% lower than apparent clinical improvement with topical antifungals. 1, 4 This means even if the nail looks better, the fungus may still be present and can recur.

Side Effects

Ciclopirox has minimal adverse effects:

  • Most common: periungual and nail fold erythema (5% of patients) 1, 2, 5
  • Rare: mild burning sensation, irritation, pruritus 5
  • No systemic adverse reactions 5

Alternative Considerations

If cost is the primary concern but you want better efficacy than ciclopirox:

  • Amorolfine 5% lacquer applied once or twice weekly for 6-12 months achieves approximately 50% effectiveness (comparable to efinaconazole but less convenient dosing) 1, 4
  • Oral terbinafine remains the most cost-effective option with highest cure rates if systemic therapy is not contraindicated 1

Bottom Line

Switch to ciclopirox if the patient has mild, limited disease (<80% nail involvement, no lunula involvement) and cost is prohibitive, but set realistic expectations about the lower cure rates and prolonged 48-week treatment course. 1, 2 For more extensive disease, strongly advocate for oral terbinafine or combination therapy to avoid treatment failure. 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Ciclopirox Treatment for Fungal Nail Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Topical Antifungal Treatments for Toenail Fungus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.